Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its plan to release second quarter 2024 financial results on August 7, 2024, after market close. The company's senior management will host a webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and provide a corporate progress update. Interested parties can access the live webcast or replay through the company's investor relations website. The replay will be available for at least 14 days following the live event.
Revolution Medicines (Nasdaq: RVMD), un'azienda oncologica in fase clinica focalizzata sullo sviluppo di terapie mirate per i tumori dipendenti da RAS, ha annunciato la sua intenzione di rilasciare i risultati finanziari del secondo trimestre 2024 il 7 agosto 2024, dopo la chiusura del mercato. La direzione senior dell'azienda ospiterà un webcast alle 16:30 ora orientale (13:30 ora del Pacifico) per discutere i risultati finanziari e fornire un aggiornamento sui progressi aziendali. Le parti interessate potranno accedere al webcast dal vivo o al replay tramite il sito web delle relazioni con gli investitori dell'azienda. La registrazione sarà disponibile per almeno 14 giorni dopo l'evento dal vivo.
Revolution Medicines (Nasdaq: RVMD), una empresa oncológica en etapa clínica centrada en desarrollar terapias dirigidas para cánceres adictos a RAS, ha anunciado su plan de publicar los resultados financieros del segundo trimestre de 2024 el 7 de agosto de 2024, después del cierre del mercado. La alta dirección de la empresa llevará a cabo un webcast a las 4:30 p.m. hora del Este (1:30 p.m. hora del Pacífico) para discutir los resultados financieros y brindar una actualización sobre el progreso corporativo. Las partes interesadas podrán acceder al webcast en vivo o a la repetición a través del sitio web de relaciones con inversores de la empresa. La repetición estará disponible durante al menos 14 días después del evento en vivo.
Revolution Medicines (Nasdaq: RVMD)는 RAS 의존성 암을 위한 표적 치료제 개발에 집중하는 임상 단계의 항암제 회사로, 2024년 2분기 재무 결과를 2024년 8월 7일 시장 마감 후 발표할 계획이라고 밝혔습니다. 회사의 고위 경영진은 동부 표준시 오후 4:30 (태평양 표준시 오후 1:30)에 재무 결과에 대해 논의하고 기업 진행 상황 업데이트를 제공하는 웹캐스트를 주최할 것입니다. 관심 있는 사람들은 회사의 투자자 관계 웹사이트를 통해 생중계 또는 재방송을 이용할 수 있습니다. 재방송은 생방송 이후 최소 14일 동안 이용 가능합니다.
Revolution Medicines (Nasdaq: RVMD), une entreprise de cancérologie en fase clinique axée sur le développement de thérapies ciblées pour les cancers dépendants de RAS, a annoncé son intention de publier les résultats financiers du deuxième trimestre 2024 le 7 août 2024, après la fermeture du marché. La direction senior de l'entreprise animera un webcast à 16h30 heure de l'Est (13h30 heure du Pacifique) pour discuter des résultats financiers et fournir une mise à jour sur les progrès de l'entreprise. Les parties intéressées peuvent accéder au webcast en direct ou à la rediffusion via le site web des relations investisseurs de l'entreprise. La rediffusion sera disponible pendant au moins 14 jours après l'événement en direct.
Revolution Medicines (Nasdaq: RVMD), ein klinisches Onkologieunternehmen, das sich auf die Entwicklung gezielter Therapien für RAS-abhängige Krebserkrankungen konzentriert, hat bekannt gegeben, dass es die Finanzergebnisse des zweiten Quartals 2024 am 7. August 2024 nach Marktbeginn veröffentlichen wird. Die Geschäftsleitung des Unternehmens wird um 16:30 Uhr Eastern Time (13:30 Uhr Pazifische Zeit) einen Webcast abhalten, um die Finanzergebnisse zu besprechen und ein Update zum Unternehmensfortschritt zu geben. Interessierte können den Live-Webcast oder die Wiederholung über die Website für Investor Relations des Unternehmens abrufen. Die Wiederholung wird mindestens 14 Tage nach der Live-Veranstaltung verfügbar sein.
- None.
- None.
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities include its RAS(ON) mutant-selective inhibitors RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
FAQ
When will Revolution Medicines (RVMD) report its Q2 2024 financial results?
What time is Revolution Medicines' (RVMD) Q2 2024 earnings webcast scheduled for?
Where can I access Revolution Medicines' (RVMD) Q2 2024 earnings webcast?
How long will the replay of Revolution Medicines' (RVMD) Q2 2024 earnings webcast be available?
